Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy

David A. Smith, Paul Conkling, Donald Richards, John Nemunaitis, Thomas E. Boyd, Alain C. Mita, Guillaume de La Bourdonnaye, David Wages, Alice Bexon

Cancer Immunology Immunotherapy · 2014 · 67 citations · 23 references

DOIFull text

Open access

Concepts

References

23